Zh Nevrol Psikhiatr Im S S Korsakova. 2025;125(9):131-138. doi: 10.17116/jnevro2025125091131.
ABSTRACT
OBJECTIVE: The aim of this study was to study the complex relationship between markers of oxidative stress and depression in patients diagnosed with Parkinson’s disease, with an emphasis on how various therapeutic interventions affect these biochemical parameters.
MATERIAL AND METHODS: The study included 60 participants (26 women and 34 men, average age 65.13±0.84 years) who received Fluvoxamine 100 mg/day as monotherapy (main group, n=30) or combination therapy (comparison group, n=30), including the antioxidant Cytoflavin and Fluvoxamine 100 mg/day. The control group consisted of 20 practically healthy elderly people. Using clinical, psychometric, and statistical research methods, the dynamics of depression symptoms and markers of oxidative stress in patients diagnosed with Parkinson’s disease were evaluated during a three-month course of treatment with Fluvoxamine and Cytoflavin.
RESULTS: During 3 months of therapy, the average score on the Hamilton depression scale in the main group decreased from 26.63±0.33 to7.22±0.5 points (p<0.01), in the comparison group from 26.51±0.29 to 12.18±1.1 points. According to the HADS scale, the average score in the main group decreased from 15.46±0.8 to 7.1±0.1 points (p<0.05), and in the comparison group from 15.14±0.8 to 9.7±1.2 points. After the therapy, all patients showed a significant slowdown in lipid peroxidation processes, an increase in the concentration of antioxidant enzymes, and a statistically significant (p<0.01) increase in the concentration of reduced glutathione, with a more significant improvement in the main group.
CONCLUSION: The results of a comparative analysis of the effectiveness of treatment of depression in patients with Parkinson’s disease showed that the use of a combination of Fluvoxamine and Cytoflavin provides a more pronounced therapeutic effect compared with Fluvoxamine monotherapy. These findings emphasize the need to integrate combined approaches into the development of new treatment strategies for depressive states based on a personalized assessment of the clinical picture of depressive disorder and biomarkers of oxidative stress.
PMID:41051815 | DOI:10.17116/jnevro2025125091131
